Hope Clinic
Atlanta, Georgia, 30322, United States
Location status: Recruiting
Location contact
Daniel Graciaa, MD
PRINCIPAL_INVESTIGATOR
Daniel Graciaa, MD, MPH, MSc
CONTACT
NCT Number: NCT06850298
The purpose of this study is to determine whether drinking pasteurized milk (milk heated to kill harmful germs) that contains inactive particles of a flu virus called A(H5) could lead to the detection of the virus in the nose or throat. Inactive particles are not capable of causing disease. The results will help the Centers for Disease Control and Prevention (CDC) better understand how milk consumption could affect flu surveillance. Investigators also want to see if the body produces antibodies in response to this milk consumption.
Interested in participating?
Request Info18 year–64 year
All sexes
Interventional
Not applicable
Atlanta, Georgia, 30322, United States
Location status: Recruiting
Daniel Graciaa, MD
PRINCIPAL_INVESTIGATOR
Daniel Graciaa, MD, MPH, MSc
CONTACT
Since March 2024, avian influenza A (H5N1) viruses have infected U.S. dairy cattle and spread widely. The virus has been identified in high concentrations in raw milk, and research shows that pasteurization - the process of heating milk to a specific temperature for a set time - inactivates the A (H5N1) virus. Therefore, the Food and Drug Administration (FDA) says that commercial pasteurized milk is safe for consumption. However, trace amounts of inactive influenza particles may still be detected in pasteurized milk.
This study aims to determine whether drinking pasteurized milk could be a possible exposure for H5N1 influenza detection. The findings will support the Centers for Disease Control and Prevention's (CDC) efforts to evaluate milk consumption as a factor in influenza surveillance and provide context for interpreting surveillance data.
Healthy adults will drink 250 mL of pasteurized milk containing the inactive H5N1 virus, provided by the CDC, either during a single visit or over three consecutive daily visits. Nasal and combined nasal/oral swabs will be collected immediately following milk consumption to assess the presence of influenza. Additionally, a subset of participants will provide blood, saliva, and stool samples at the initial visit and again 21-30 days post-consumption.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Milk to be used in the study will be obtained from the CDC. Pasteurized commercial milk likely to contain detectable A(H5N1) particles will be obtained from a source such as a recently affected dairy farm. The CDC Influenza Division laboratory (Viral, Surveillance, and Diagnosis Branch) will test the milk to confirm the presence of viral A(H5) RNA using a protocol developed and validated by the US FDA Agricultural Research Service. The US Food and Drug Administration (FDA) has indicated that the consumption of commercial pasteurized dairy products in the US is safe.
Time frame: Up to 30 days after milk consumption
Proportion of respiratory specimens (nasopharyngeal and combined nasal/oropharyngeal swabs) with detection of influenza after consumption of pasteurized milk contaminated with killed A(H5) virus
Time frame: Up to 30 days after milk consumption
Participants will be asked to call the site if they develop any adverse events for the entire the study participation.
Contact information is provided by the study sponsor or research team.
Emory University
Other
Investigation of Impact of Milk Consumption on H5 Influenza Detection in Respiratory Specimens
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07215858
Human, Infections
Bethesda, Maryland, United States
View Trial DetailsNCT01386424
Arbovirus Infections, Flaviviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07485855
Hematologic Diseases, Hematologic Neoplasms
Seoul, South Korea
View Trial DetailsNCT07110532
Infections, Influenza
Baltimore, Maryland, United States
View Trial Details